Investors

Global Links


Management Team

Investors

Press Releases

DateSubject
October 31, 2002 Cerus Corporation Receives Commitment for $50 Million Financing From Baxter
October 31, 2002 Cerus Corporation Announces Third Quarter Results
October 24, 2002 Webcast Alert: Cerus Corporation Announces Third Quarter Financial Results Conference Call
October 23, 2002 Cerus Corporation Appoints Elizabeth M. Tillson, Ph.D. as Vice President, Regulatory Affairs and Quality
October 16, 2002 Baxter and Cerus Announce Final European Regulatory Clearance for the First Pathogen Inactivation System for Platelets
September 26, 2002 Cerus Corporation Receives $6.5 Million Award in Expanded Collaboration With the U.S. Armed Forces
July 31, 2002 Cerus Corporation Announces Second Quarter Results
July 17, 2002 Cerus Corporation Invites You to Join a Webcast of Its Second Quarter Conference Call.
July 11, 2002 Cerus Corporation Receives $5 Million Milestone Payment From Baxter Healthcare Corporation
June 26, 2002 Cerus Corporation Expands U.S. Patent Coverage for Pathogen Inactivation in Blood
June 4, 2002 Cerus Invites You to a Company Update via the Web
June 4, 2002 Cerus and Baxter's INTERCEPT Disposable Set for Platelets Receives European Regulatory Approval.
April 25, 2002 Cerus Corporation Announces First Quarter Results
April 12, 2002 Cerus Corporation Invites You to Join a Webcast of its First Quarter Conference Call
April 11, 2002 Cerus Corporation Names William R. Rohn to Board of Directors
February 21, 2002 Cerus and Baxter Receive FDA Concurrence to Begin Phase III INTERCEPT Red Blood Cell Trial in Chronic Indications
January 24, 2002 Cerus Corporation Announces Fourth Quarter and Year End 2001 Results
January 14, 2002 Cerus Corporation Invites You to Join a Webcast of Its Fourth Quarter Conference Call
January 9, 2002 Cerus and Baxter Initiate Clinical Site in Pivotal Phase III Trial for INTERCEPT Red Blood Cell System